PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Protagonist Therapeutics, Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$134.44+5.69 (+4.42%)
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
76M of 65M shares
Institutional holders
343
63 new, 36 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 35 sales
Net sold $86.91M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 8,575,669 | 13.80% | 13G (passive) amendment | Sep 30, 2025 |
| Wehrly, Mark C. | 6,433,119 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Linn, Michael G. | 5,956,488 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Roderick Wong | 5,059,053 | 8.10% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Portfolio Management | 3,533,015 | 5.53% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | 3,321,554 | 5.20% | 13G (passive) | Jun 30, 2026 |
| Vanguard Capital Management | 3,250,003 | 5.09% | 13G (passive) | Mar 31, 2026 |
| David Kroin | 3,250,000 | 5.29% | 13G (passive) | Apr 3, 2025 |
| Lampert Mark N | 3,211,041 | 5.20% | 13G (passive) | Jun 9, 2025 |
| Wellington Investment Advisors Holdings LLP | 3,171,423 | 5.10% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PTGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10,307,837 | 15.93% | $1.26B | +528,468 | 0.02% |
| Farallon Capital Management LLC | 6,348,906 | 9.81% | $778.25M | – | 3.59% |
| Rtw Investments, LP | 5,061,175 | 7.82% | $620.40M | +2,122 | 5.30% |
| Vanguard Portfolio Management LLC | 3,629,298 | 5.61% | $444.88M | +148,087 | 0.02% |
| Wellington Management Group Llp | 3,416,781 | 5.28% | $418.83M | −182,863 | 0.07% |
| UBS Group AG | 3,399,221 | 5.25% | $416.68M | −1,778,575 | 0.05% |
| State Street Corp | 3,321,554 | 5.13% | $407.16M | +204,805 | 0.01% |
| Vanguard Capital Management LLC | 2,853,394 | 4.41% | $349.77M | +47,498 | 0.01% |
| Johnson & Johnson | 2,449,183 | 3.78% | $300.22M | – | 37.59% |
| Invesco Ltd. | 2,340,667 | 3.62% | $286.92M | +175,997 | 0.02% |
| Price T Rowe Associates Inc /Md/ | 2,149,662 | 3.32% | $263.51K | +484,165 | 0.03% |
| Jupiter Topco LLC | 2,129,780 | 3.29% | $261.04M | New | 0.11% |
| Geode Capital Management, LLC | 1,741,209 | 2.69% | $213.48M | +71,838 | 0.01% |
| Woodline Partners LP | 1,414,173 | 2.19% | $173.35M | – | 0.54% |
| Bank Of America Corp /De/ | 1,324,498 | 2.05% | $162.36M | +29,064 | 0.01% |
| Jennison Associates LLC | 1,151,681 | 1.78% | $141.17M | +79,670 | 0.08% |
| Perceptive Advisors LLC | 981,879 | 1.52% | $120.36M | −249,000 | 1.81% |
| ADAR1 Capital Management, LLC | 960,863 | 1.48% | $117.78M | −33,256 | 5.39% |
| Morgan Stanley | 905,992 | 1.40% | $111.06M | −112,230 | 0.01% |
| Alyeska Investment Group, L.P. | 889,298 | 1.37% | $109.01M | +296,101 | 0.28% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 343 | 76M | 100.0% | 63 / 140 | 88 / 36 | 7M | 8M |
| Q1 2026 | 320 | 79M | 100.0% | 60 / 110 | 103 / 49 | 18M | 4M |
| Q4 2025 | 316 | 71M | 100.0% | 84 / 97 | 103 / 39 | 12M | 12M |
| Q3 2025 | 275 | 71M | 100.0% | 42 / 85 | 108 / 38 | 7M | 7M |
| Q2 2025 | 273 | 71M | 100.0% | 51 / 119 | 77 / 49 | 11M | 6M |
| Q1 2025 | 275 | 65M | 100.0% | 72 / 84 | 92 / 34 | 10M | 8M |
| Q4 2024 | 241 | 64M | 98.6% | 45 / 91 | 76 / 41 | 7M | 6M |
| Q3 2024 | 240 | 62M | 96.3% | 79 / 77 | 64 / 24 | 21M | 12M |
| Q2 2024 | 188 | 59M | 91.9% | 30 / 63 | 68 / 26 | 7M | 12M |
| Q1 2024 | 185 | 64M | 98.9% | 49 / 62 | 56 / 20 | 13M | 8M |
| Q4 2023 | 156 | 59M | 91.4% | 32 / 40 | 60 / 19 | 11M | 9M |
| Q3 2023 | 144 | 57M | 87.7% | 17 / 66 | 40 / 40 | 10M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of PTGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 3,641,824 | 5.63% | $446.41M | 0.40% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,044,938 | 3.16% | $250.67M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,579,849 | 2.44% | $193.66M | 0.23% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,475,422 | 2.28% | $180.86M | 0.10% | Jun 30, 2026 |
| Vanguard Health Care Fund | 1,243,618 | 1.92% | $169.93M | 0.45% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 941,367 | 1.45% | $115.39M | 1.07% | Jun 30, 2026 |
| Vanguard Explorer Fund | 881,156 | 1.36% | $120.40M | 0.54% | Jul 31, 2026 |
| Vanguard Small-Cap Growth Index Fund | 849,902 | 1.31% | $104.18M | 0.22% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 828,559 | 1.28% | $101.56M | 0.85% | Jun 30, 2026 |
| Invesco Discovery Fund | 810,087 | 1.25% | $80.65M | 1.03% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 693,466 | 1.07% | $85.01M | 0.09% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 672,659 | 1.04% | $91.91M | 0.27% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 607,713 | 0.94% | $60.50M | 1.15% | May 31, 2026 |
| Invesco S&P SmallCap Momentum ETF | 569,778 | 0.88% | $77.85M | 2.57% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 568,174 | 0.88% | $69.65M | 0.45% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dinesh V. Ph D. Patel | President and CEO, Director | 522,968 | 0.81% | Sep 10, 2026 |
| Asif Ali | Chief Financial Officer | 59,003 | 0.09% | Apr 21, 2026 |
| Arturo Molina Md | Chief Medical Officer | 99,115 | 0.15% | Mar 27, 2026 |
| Suneel Gupta | Chief Development Officer | 267,433 | 0.41% | Nov 27, 2024 |
| William D. Waddill | Director | 7,825 | 0.01% | Jun 25, 2026 |
| Bryan Giraudo | Director | 12,695 | 0.02% | May 11, 2026 |
| Harold E. Selick | Director | 84,845 | 0.13% | Mar 27, 2026 |
| Lewis T. Williams | Director | 7,825 | 0.01% | Feb 18, 2026 |
| Sarah A. O'Dowd | Director | 7,825 | 0.01% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −7,278 | $144.10 | $1.05M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 10, 2026 | Option exercise | +7,278 | $21.58 | $157.06K | 530,246 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 9, 2026 | Option exercise | +63,548 | $21.58 | $1.37M | 586,516 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −63,548 | $146.18 | $9.29M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 8, 2026 | Option exercise | +54,174 | $21.58 | $1.17M | 577,142 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −54,174 | $145.87 | $7.90M | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Sep 3, 2026 | Gift | −510 | – | – | 522,968 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 11, 2026 | Option exercise | +34,239 | $21.58 | $738.88K | 557,717 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −34,239 | $148.52 | $5.09M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −65,761 | $149.11 | $9.81M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | Aug 10, 2026 | Option exercise | +65,761 | $21.58 | $1.42M | 589,239 |
| William D. Waddill Director | Jun 23, 2026 | Sale(10b5-1 plan) | −9,000 | $117.94 | $1.06M | 7,825 |
| William D. Waddill Director | Jun 23, 2026 | Option exercise | +9,000 | $16.54 | $148.86K | 16,825 |
| William D. Waddill Director | Jun 10, 2026 | Option exercise | +6,000 | $16.54 | $99.24K | 16,825 |
| William D. Waddill Director | Jun 10, 2026 | Sale(10b5-1 plan) | −9,000 | $107.68 | $969.12K | 7,825 |
| William D. Waddill Director | Jun 10, 2026 | Option exercise | +3,000 | $11.80 | $35.40K | 10,825 |
| William D. Waddill Director | May 29, 2026 | Option exercise | +9,000 | $11.80 | $106.20K | 16,825 |
| William D. Waddill Director | May 29, 2026 | Sale(10b5-1 plan) | −9,000 | $99.64 | $896.76K | 7,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Option exercise | +75,000 | $21.58 | $1.62M | 598,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Sale(10b5-1 plan) | −75,000 | $100.12 | $7.51M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Sale | −75,000 | $100.12 | $7.51M | 523,478 |
| Dinesh V. Ph D. Patel President and CEO, Director | May 12, 2026 | Option exercise | +75,000 | $21.58 | $1.62M | 598,478 |
| Bryan Giraudo Director | May 8, 2026 | Sale | −6,000 | $100.00 | $600.00K | 0 |
| Bryan Giraudo Director | May 8, 2026 | Sale | −5,130 | $100.00 | $513.00K | 12,695 |
| Bryan Giraudo Director | May 7, 2026 | Sale | −12,000 | $100.07 | $1.20M | 6,000 |
| Bryan Giraudo Director | May 7, 2026 | Sale | −36,000 | $100.14 | $3.61M | 27,825 |
| Bryan Giraudo Director | May 7, 2026 | Option exercise | +12,000 | $6.98 | $83.76K | 43,825 |
| Bryan Giraudo Director | May 7, 2026 | Option exercise | +24,000 | $6.45 | $154.80K | 31,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | Apr 23, 2026 | Gift | −1,460 | – | – | 523,478 |
| Asif Ali Chief Financial Officer | Apr 20, 2026 | Sale | −1,750 | $105.47 | $184.57K | 59,003 |
| Harold E. Selick Director | Mar 26, 2026 | Option exercise | +24,000 | $12.88 | $309.12K | 84,845 |
| Harold E. Selick Director | Mar 26, 2026 | Sale | −24,000 | $105.00 | $2.52M | 60,845 |
| Arturo Molina Md Chief Medical Officer | Mar 26, 2026 | Option exercise | +15,000 | $8.04 | $120.60K | 99,115 |
| Arturo Molina Md Chief Medical Officer | Mar 26, 2026 | Sale | −15,000 | $104.79 | $1.57M | 84,115 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Option exercise | +19,500 | $19.19 | $374.21K | 80,253 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Option exercise | +5,265 | $12.17 | $64.08K | 85,518 |
| Asif Ali Chief Financial Officer | Mar 26, 2026 | Sale | −24,765 | $104.24 | $2.58M | 60,753 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 25, 2026 | Option exercise | +54,641 | $8.58 | $468.82K | 579,579 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 25, 2026 | Sale | −54,641 | $101.00 | $5.52M | 524,938 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 24, 2026 | Sale | −59 | $101.00 | $5.96K | 524,938 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 24, 2026 | Option exercise | +59 | $8.58 | $506 | 524,997 |
| Dinesh V. Ph D. Patel President and CEO, Director | Mar 23, 2026 | Gift | −50,000 | – | – | 524,938 |
| Lewis T. Williams Director | Feb 17, 2026 | Sale | −18,000 | $82.42 | $1.48M | 7,825 |
| Lewis T. Williams Director | Feb 17, 2026 | Option exercise | +18,000 | $10.84 | $195.12K | 25,825 |
| William D. Waddill Director | Feb 6, 2026 | Sale | −20,000 | $83.68 | $1.67M | 7,825 |
| William D. Waddill Director | Feb 6, 2026 | Option exercise | +20,000 | $8.31 | $166.20K | 27,825 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 27, 2026 | Option exercise | +4,068 | $21.58 | $87.79K | 578,573 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 27, 2026 | Sale | −4,068 | $83.19 | $338.42K | 574,505 |
| Arturo Molina Md Chief Medical Officer | Jan 27, 2026 | Option exercise | +5,000 | $8.04 | $40.20K | 89,115 |
| Arturo Molina Md Chief Medical Officer | Jan 27, 2026 | Sale | −5,000 | $82.00 | $410.00K | 84,115 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Sale | −18,203 | $83.14 | $1.51M | 60,320 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Sale | −28,000 | $83.13 | $2.33M | 78,523 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Option exercise | +16,000 | $19.19 | $307.04K | 94,523 |
| Asif Ali Chief Financial Officer | Jan 27, 2026 | Option exercise | +12,000 | $12.17 | $146.04K | 106,523 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 26, 2026 | Sale | −14,205 | $84.05 | $1.19M | 574,505 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 26, 2026 | Option exercise | +14,205 | $21.58 | $306.54K | 588,710 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 26, 2026 | Sale | −10,685 | $84.00 | $897.54K | 574,505 |
| Dinesh V. Ph D. Patel President and CEO, Director | Jan 26, 2026 | Option exercise | +10,685 | $4.21 | $44.98K | 585,190 |
| Arturo Molina Md Chief Medical Officer | Jan 26, 2026 | Option exercise | +5,000 | $8.04 | $40.20K | 89,115 |
| Arturo Molina Md Chief Medical Officer | Jan 26, 2026 | Sale | −5,000 | $82.28 | $411.40K | 84,115 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ali Asif Officer | Sep 30, 2026 | 58,629 | $8.26M | Sep 30, 2026 | Exercise of Stock Options |
| Patel Dinesh CEO | Aug 10, 2026 | 225,000 | $33.58M | Aug 10, 2026 | Option Exercise |
| Waddill William Director | Jun 23, 2026 | 9,000 | $1.04M | Jun 23, 2026 | Exercise of Stock Options |
| Waddill William Director | Jun 10, 2026 | 9,000 | $952.83K | Jun 10, 2026 | Exercise of Stock Options |
| Waddill William Director | May 29, 2026 | 9,000 | $903.69K | May 29, 2026 | Exercise of Stock Options |
| Patel Dinesh CEO | May 12, 2026 | 75,000 | $7.76M | May 12, 2026 | Option Exercise |
| M. & Courtney L. Giraudo Rt Bryan Director | May 8, 2026 | 11,130 | $1.11M | May 8, 2026 | Compensation |
| Giraudo Bryan Director | May 7, 2026 | 36,000 | $3.60M | May 7, 2026 | Stock Option Exercise |
| M. & Courtney L. Giraudo Rt Bryan Director | May 7, 2026 | 12,000 | $1.20M | May 7, 2026 | Compensation |
| Ali Asif Officer | Apr 21, 2026 | 1,750 | $184.57K | Apr 20, 2026 | Restricted stock vesting under a registered plan |
| Selick Harold Director | Mar 26, 2026 | 24,000 | $2.52M | Mar 26, 2026 | Stock Option Exercise |
| Molina Arturo Officer | Mar 26, 2026 | 15,000 | $1.57M | Mar 26, 2026 | Stock Option Exercise |
| Ali Asif Officer | Mar 26, 2026 | 24,765 | $2.58M | Mar 26, 2026 | Stock Option Exercise |
| Patel Dinesh CEO | Mar 24, 2026 | 54,700 | $5.39M | Mar 24, 2026 | Option Exercise |
| T. Williams Lewis Director | Feb 17, 2026 | 18,000 | $1.48M | Feb 17, 2026 | Stock Option Exercise |